This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ThousandOaks-based biotech giant Amgen has backed a developer of therapeutic antibodies, via its venture capital arm, Amgen Ventures. Other investors in the round were ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, and Zenyaku Kogyo. READ MORE>>.
ThousandOaks-based Ceres , a developer of biofuel crop technology, has raised another $20M in funding, according to a regulatory filing from the firm Friday. Ceres has previously raised funds from Warburg Pincus, Soros Private Equity, QuestMark Partners, Oxford BioScience, Oppenheimer, Monsanto, KBC, H&Q, and GIMV.
ThousandOaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. immungene venture capital biotech biotechnology cancer therapeutics' to its board of directors.
ThousandOaks-based Ceres , a developer of biofuel crop technology, and Novozymes , a developer of enzymes, said today that the two have entered into a research collaboration around cellulosic biofuel production. Financial details of the partnership were not disclosed. READ MORE>>.
The firm, which is based in Northern California but has major operations in ThousandOaks, said that Elevation will continue to hold $50M in Series B preferred stock in the firm. Move said the moves are part of a plan to "streamline" its capital structure. Move, Inc. ,
ThousandOaks-based SunBrite TV , a manufacturer of large screen, HDTV screens specifically designed to be installed outdoors, next to pools, on patios, and elsewhere, has been acquired by SnapAV , which is owned by private equity investor General Atlantic. SunBriteTV was backed by Bunker Hill Capital. READ MORE>>.
ThousandOaks-based wireless networking equipment maker Xirrus has been acquired by Riverbed , to help bolster its SD WAN efforts, the two said on Wednesday. Financial terms of the acquisition were not announced. Riverbed said it will continue to offer up Xirrus as a stand-alone enterprise WLAN solution.
I grew up in ThousandOaks, went to USC, and we met each other way back in the 90's. Where there are lots of players focused on different types of equity, different types of investments, different types of debt, they're doing it in a very unfocused manner. Brew Johnson: It's exciting to be building this business in LA.
It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment. And in other Amgen news, the ThousandOaks, CA, company filed for FDA approval of osteoporosis drug romosuzumab.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content